Borgstrom L, Kagedal B, Paulsen O Pharmacokinetics of NAS in man. Eur. J. Clin. Pharmacol 1986; 31: 217-222
Olivieri D. et.al. Improvement of mucociliary transport in smokers by mucolytics. Eur. J. Respir. Dis. 66 (Suppl. 139): 142-145, 1985
Brocard H. et. Al. Acute indications for Acetylcysteine – Etude multi-centrique en double aveugle avee acetylcysteine orale vs placebo. Eur. J. Resp. Dis. 61 (Suppl. 111); 65-69, 1980
Kasielski M et. al. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exalation in subjects with chronic obstructive pulmonary disease. Resp. Med. 95: 448-456, 2001
Briedgeman M.M. et.al. Cysteine and gluthathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46: 39-42, 1991
Gerrits C. M. J. M. et. Al. N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstructive pulmonary disease. Eur. Respir. J.21: 795-798, 2003
Stey C et. Al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Zuin P. et. Al. High-dose N-acetylcysteine in patients with exacerbation of chronic obstructive pulmonary disease. Clin. Drug invest: 25: 401-408, 2005.
www.fluimucil.it/en/History
https://en.wikipedia.org/wiki/Acetycysteine
Zheng JP et.al. Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomized, double-blind placebo-controlled trial. Lancet Respir Med 2014;2:187-94
Hoi Nam Tse et. al. High-dose N-acetylcysteine in stable COPD: The 1-Year, Double-Blind, Randomized, Placebo-Controlled HIACE Study. CHEST 2013;144(1):106-118
Jan De Backer et. al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of COPD 2013:8 569-579
References
Borgstrom L, Kagedal B, Paulsen O Pharmacokinetics of NAS in man. Eur. J. Clin. Pharmacol 1986; 31: 217-222
Olivieri D. et.al. Improvement of mucociliary transport in smokers by mucolytics. Eur. J. Respir. Dis. 66 (Suppl. 139): 142-145, 1985
Brocard H. et. Al. Acute indications for Acetylcysteine – Etude multi-centrique en double aveugle avee acetylcysteine orale vs placebo. Eur. J. Resp. Dis. 61 (Suppl. 111); 65-69, 1980
Kasielski M et. al. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exalation in subjects with chronic obstructive pulmonary disease. Resp. Med. 95: 448-456, 2001
Briedgeman M.M. et.al. Cysteine and gluthathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46: 39-42, 1991
Gerrits C. M. J. M. et. Al. N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstructive pulmonary disease. Eur. Respir. J.21: 795-798, 2003
Stey C et. Al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Zuin P. et. Al. High-dose N-acetylcysteine in patients with exacerbation of chronic obstructive pulmonary disease. Clin. Drug invest: 25: 401-408, 2005.
www.fluimucil.it/en/History
https://en.wikipedia.org/wiki/Acetycysteine
Zheng JP et.al. Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomized, double-blind placebo-controlled trial. Lancet Respir Med 2014;2:187-94
Hoi Nam Tse et. al. High-dose N-acetylcysteine in stable COPD: The 1-Year, Double-Blind, Randomized, Placebo-Controlled HIACE Study. CHEST 2013;144(1):106-118
Jan De Backer et. al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of COPD 2013:8 569-579
